Two recent U.S. regulatory actions broaden nonhormonal treatment options for menopausal vasomotor symptoms. The FDA approved elinzanetant, a nonhormonal agent shown in multinational trials to reduce hot flashes and night sweats, and separately cleared Bayer’s Lynkuet, the company’s dual neurokinin-targeted therapy for menopausal hot flashes. Both approvals follow pivotal trial data reported across clinical sites and reflect regulators’ willingness to approve alternatives to hormone therapy. The decisions will affect commercial positioning for women’s‑health portfolios and give clinicians additional nonhormonal options for symptomatic management.